

Title: TRALI Risk Mitigation Policy		
Document #: POL-00100	Department: Donor Services	Category: Apheresis
Version: 2	Effective: Mar 24, 2026	Phase: Approved

Updated February 2026

The Northern California Community Blood Bank (NCCBB) is committed to providing a safe and adequate supply of blood and blood products. In accordance with AABB Standards, NCCBB employs the following strategy to reduce the incidence of Transfusion-related Acute Lung Injury (TRALI):

- Transfusable apheresis plasma and platelets are collected from donors who have never been pregnant, or who have tested negative for the human leukocyte antigen (HLA) antibody.
- Any donor who has been pregnant will be tested for antibodies to HLA prior to donating apheresis plasma or platelets (AABB Standard 5.4.1.3).
- Donors will be re-tested for the HLA antibody after pregnancies subsequent to their last HLA antibody test.
- Donors who test positive for the HLA antibody will be excluded from donating apheresis plasma or platelets.
- A thorough investigation of all possible TRALI cases reported to NCCBB will be evaluated including the implicated or associated donor's ability to continue donating (AABB Standard 5.4.1.2).
- Transfusable plasma from whole blood will be collected only from donors who have never been pregnant.

References:

- AABB Association Bulletin #14-02
- AABB Standard 5.1.4.3, 5.4.1.2